Shizim Group Company Profile

Background

Shizim Group, established in 2000 by Yossi Bornstein, is Israel's leading integrated Life Sciences and Health Tech holding company. The group is deeply embedded in the biomedical ecosystem, both domestically and internationally. Its mission is to identify and bring breakthrough medical device and digital health technologies to market, thereby enhancing patient care and advancing the healthcare industry.

Key Strategic Focus

Shizim Group's strategic focus encompasses:

Innovation Centers: Operating centers like ShizimXL for medical devices and ShizimVS for digital health technologies, the group nurtures startups from early-stage concepts to commercialization.

Contract Research Organization (CRO) Services: Through GCP Clinical Studies Ltd., Shizim offers full-service CRO capabilities to multinational pharmaceutical and medical device companies.

Pharmaceutical and Medical Device Distribution: Companies like Dolphin Medical and Biotis handle the marketing and distribution of products from multinational corporations.

Education and Training: Collaborating with institutions such as the Technion, Shizim provides advanced education and training programs for medical professionals, investors, and entrepreneurs.

Medical Cannabis Ventures: Through Cann10, the group engages in medical cannabis investment, R&D, global trade, education, and partnerships.

Financials and Funding

Shizim Group operates as a privately held entity. While specific financial details are not publicly disclosed, the group has a history of successful ventures, including the NASDAQ listing of Microbot Medical (NASDAQ: MBOT) and achieving FDA and CE approvals for XACT Robotics, which is currently in the sales stage in the U.S.

Pipeline Development

Shizim Group's innovation centers support a diverse portfolio of startups at various stages of development. Notable companies include:

NerveSense: Developing a smart nerve-sparing surgical cutting tool.

Skelable: Creating a remote exoskeleton for hand rehabilitation and support in daily activities.

SensPD: Utilizing adaptive algorithms and big data to objectively detect autism soon after birth.

Triticum: Innovating a clot retriever for treating acute ischemic stroke and occlusions in peripheral vessels.

Nurotone: Advancing an optical cochlear implant to restore hearing in the deaf.

Dasyo: Producing home-use, non-invasive directional skin tightening devices for aesthetic needs.

Yama+: Offering natural Dead Sea toothpaste with essential oils to treat gum diseases.

Stimulep: Reducing epileptic seizures during sleep using neuromodulation therapy.

3DSIL: Providing a 3D printing platform for manufacturing silicone implants.

Stand3lone: Developing lower-limb prosthesis fitting during weight-bearing.

CognigGuard: Combining therapies for the effective treatment of Alzheimer's Disease.

Technological Platform and Innovation

Shizim Group distinguishes itself through:

Proprietary Technologies: Supporting startups that develop unique medical devices and digital health solutions.

Scientific Methodologies: Employing advanced research and development practices, including adaptive algorithms and big data analytics.

AI-Driven Capabilities: Leveraging artificial intelligence in diagnostics and treatment planning, particularly in digital health ventures.

Leadership Team

Tamir Pardo: Chairman. Former Head of the Mossad, with experience in cyber security ventures and academia.

Yossi Bornstein: Founder and President. Former CEO of Bristol-Myers Squibb in Israel, co-founder of Microbot Medical, and former chairman of the Biotechnology Committee of the US-Israel Science and Technology Commission.

Kobi Caspi: Partner, Director & CFO. Co-founder of ShizimXL Innovation Center, with experience in global investment companies.

Doron Ben Ami: Partner, Director, CEO of ShizimXL & ShizimVS. Former executive in multinational pharma companies and medical device entrepreneur.

Rotem Caspi Shomrat: VP, Finance. Formerly with Ernst & Young, specializing in high-tech audit services.

Dr. Shuki Yeshurun: CSO, Shizim Innovation Centers. Former CTO in various organizations, including Israel's Directorate of Defense Research & Development.

Leadership Changes

No recent significant leadership changes have been reported.

Competitor Profile

Market Insights and Dynamics

The global health tech industry is experiencing rapid growth, driven by technological advancements and increasing healthcare demands. Israel, known as the "Startup Nation," hosts approximately 1,500 life science companies, contributing significantly to this dynamic landscape.

Competitor Analysis

Key competitors in the Israeli health tech sector include:

OurCrowd: A global venture investing platform that supports startups across various sectors, including health tech.

Trendlines Group: Focuses on developing and investing in medical and agricultural technologies.

MedX Ventures Group: Specializes in medical device innovation and commercialization.

These entities, like Shizim Group, provide support to startups through funding, mentorship, and access to global markets.

Strategic Collaborations and Partnerships

Shizim Group has established significant collaborations to enhance its market position and innovation capacity:

RITS Collaboration: Partnered with the Research Institute of Tsinghua University in Shenzhen, China, to create a pathway for medical device and digital health technologies between Israel and China. This collaboration focuses on identifying Israeli technologies suitable for the Chinese and Asian markets, providing support in R&D, manufacturing, marketing, business development, and commercialization.

Academic Partnerships: Collaborates with institutions like the Technion to provide advanced education and training programs for medical professionals, investors, and entrepreneurs.

Operational Insights

Shizim Group's integrated ecosystem offers a comprehensive suite of services, including innovation centers, CRO services, distribution channels, and educational programs. This holistic approach provides startups with the necessary resources to navigate the complex health tech landscape, from concept to commercialization. The group's extensive global network and strategic partnerships further strengthen its market position and competitive advantage.

Strategic Opportunities and Future Directions

Looking ahead, Shizim Group aims to:

Expand Innovation Centers: Continue identifying and supporting disruptive medtech and digital health startups, with a focus on technologies that can significantly impact patient care.

Strengthen Global Partnerships: Enhance collaborations with international institutions and corporations to facilitate market entry and expansion for portfolio companies.

Advance Medical Cannabis Ventures: Leverage expertise in medical cannabis to explore new investment opportunities, R&D initiatives, and global trade partnerships.

Enhance Educational Programs: Develop and offer advanced training programs to equip medical professionals and entrepreneurs with the skills needed to succeed in the evolving health tech industry.